Unique ID issued by UMIN | UMIN000002963 |
---|---|
Receipt number | R000003426 |
Scientific Title | Prospective, randomized, open-label, clinical trial evaluating the effects of pioglitazone on progression of atherosclerotic plaques, endothelial function, and markers for anti-inflammatory properties/obesity/antioxidative properties |
Date of disclosure of the study information | 2010/01/03 |
Last modified on | 2020/05/18 13:59:08 |
Prospective, randomized, open-label, clinical trial evaluating the effects of pioglitazone on progression of atherosclerotic plaques, endothelial function, and markers for anti-inflammatory properties/obesity/antioxidative properties
Prospective, randomized, open-label, clinical trial evaluating the effects of pioglitazone
Prospective, randomized, open-label, clinical trial evaluating the effects of pioglitazone on progression of atherosclerotic plaques, endothelial function, and markers for anti-inflammatory properties/obesity/antioxidative properties
Prospective, randomized, open-label, clinical trial evaluating the effects of pioglitazone
Japan |
diabetes
Cardiology |
Others
NO
Prospective, randomized, open-label, clinical trial evaluating the effects of pioglitazone on progression of atherosclerotic plaques, endothelial function, markers for anti-inflammatory properties/obesity/antioxidative properties
Efficacy
Phase IV
Area of atherosclerotic plaques in aorta detected by magnetic resonance imaging (MRI), 12/24 months after randomization
Serum lipids (total/LDL/HDL-cholesterol, triglycerides), 6/12/24 months after randomization
Flow-mediated vasodilation in forearm, 6 months after randomization
Heparin-releasable EC-SOD levels, 6 months after randomization
Markers indicating obesity (e.g. adiponectin), inflammation (high sensitive CRP), oxidative stress (8-OHdG/ MDA-LDL), early-staged kidney diseases (microalbuminuria), 6/12/24 months after randomization
Interventional
Parallel
Randomized
Open -but assessor(s) are blinded
No treatment
2
Treatment
Medicine |
Administration of pioglitazone
No administration
20 | years-old | < |
80 | years-old | > |
Male and Female
1) Diabetic patients diagnosed according to Japan Diabetes Society Guidelines
2) Outpatients
3) Subjects who gave written informed consent
1) Allergy against pioglitazone
2) Administration of pioglitazone
3) Poor-controlled hypertension (DBP>110 mmHg)
4) Poor-controlled diabetes (HbA1c>10.0 %)
5) History of stroke, acute coronary syndrome or any cardiovascular diseases needed for inpatient-treatments within 6 months
6) Either level of aspartate aminotransaminase or alanine aminotransferase exceeds three-fold of the normal limits.
7) End stage renal disease
8) Symptomatic (NYHA III or IV) congestive heart failure
9) Malignancies or other diseases with poor prognosis
10) Pregnant
11) Subjects whose doctor in charge do not agree to join the trial
60
1st name | |
Middle name | |
Last name | Katsunori Ikewaki |
National Defense Medical College
Department of Internal Medicine I
3-2 Namiki, Tokorozawa, JAPAN 359-8513
1st name | |
Middle name | |
Last name | Makoto Ayaori |
National Defense Medical College
Department of Internal Medicine I
3-2 Namiki, Tokorozawa, JAPAN 359-8513
04-2995-1597
ayaori@ndmc.ac.jp
National Defense Medical College
Foundation for Promotion of Defense Medicine
Non profit foundation
Japan
NO
2010 | Year | 01 | Month | 03 | Day |
Unpublished
Completed
2009 | Year | 12 | Month | 10 | Day |
2007 | Year | 07 | Month | 31 | Day |
2010 | Year | 01 | Month | 01 | Day |
2012 | Year | 12 | Month | 01 | Day |
2010 | Year | 01 | Month | 02 | Day |
2020 | Year | 05 | Month | 18 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000003426